Highest-materiality recent filing
Haemonetics combines Plasma and Blood Center segments into Apheresis; Hospital renamed MedSurg
The new Apheresis segment combines formerly separate Plasma and Blood Center segments, effective Q1 FY2027.
Haemonetics announces Q4 and FY2026 results; financial details not provided in filing text
Press release issued on May 7, 2026 for quarter and fiscal year ended March 28, 2026.
Haemonetics director Charles Dockendorff will not stand for re-election at 2026 annual meeting
Charles J. Dockendorff, Board member since 2014, will not stand for re-election at the 2026 Annual Meeting.
Haemonetics repays $300M of 0.00% convertible notes at maturity
Repaid $300M principal of 0.00% Convertible Senior Notes due 2026 at maturity on March 2, 2026.
Haemonetics publishes 2024-2025 Corporate Responsibility Report
Report covers environmental, social, and governance initiatives; no financial data included.
Haemonetics reports Q3 results; specifics not available from provided text
Press release dated February 5, 2026, furnished as Exhibit 99.1 for Q3 and nine months ended December 27, 2025.
Haemonetics acquires Vivasure Medical for up to €185M; upfront €100M plus €85M earn-out
Acquired all equity of Vivasure Medical, a Galway, Ireland-based developer of percutaneous vessel closure technology.
Haemonetics announces Q2 FY2026 results; no figures in provided text
The company issued a press release on November 6, 2025 for its second quarter ended September 27, 2025.
Haemonetics reports Q1 FY2026 results; press release details not provided in filing text
Haemonetics issued press release on Aug 7, 2025 for Q1 ended June 28, 2025.
All nine nominees elected with 42.6-43.8M votes; broker non-votes 1.76M.
Haemonetics approves restructuring $20M charges; targets $30M annual savings
Board approved market and regional alignment initiative in May 2025.
Haemonetics appoints Frank Chan as EVP COO, promotes Roy Galvin to CCO
Frank Chan appointed EVP COO effective April 7, 2025; oversees R&D, regulatory, global manufacturing & supply chain.
Haemonetics issues Q3 FY2025 earnings press release; no details available in input
Filing reports results for Q3 and nine months ended December 28, 2024, via press release.
Haemonetics completes sale of whole blood assets to GVS for up to $67.8M
Total cash consideration up to $67.8M: $45.3M upfront (adjusted) plus up to $22.5M contingent.
Haemonetics EVP Global Manufacturing to retire July 11, 2025
Josep Llorens, EVP Global Manufacturing and Supply Chain, notified retirement effective July 11, 2025.
Haemonetics sells whole blood assets to GVS for $44.6M cash plus up to $22.5M earnout
Total consideration up to $67.1M: $44.6M cash at close plus up to $22.5M contingent on sales growth and milestones.
Haemonetics announces Q2 FY2025 results; specific figures unavailable from provided filing text
Company issued press release for quarter ended Sept 28, 2024 and first half of fiscal 2025.
Haemonetics CTO Anila Lingamneni to depart on November 1, 2024
Anila Lingamneni, EVP and Chief Technology Officer, will leave Haemonetics effective November 1, 2024.
Haemonetics reports Q1 FY2025 results; details in press release not provided
Filed 8-K on August 8, 2024 for quarter ended June 29, 2024.
Haemonetics shareholders elect directors, approve executive pay and auditor at 2024 annual meeting
All 9 director nominees elected with ~47.1M–47.6M votes each; no director received less than 46.8M for.
All nine Haemonetics directors elected; say-on-pay and auditor ratification pass
Quorum of 95.99% (48.9M of 50.95M shares) represented at the July 25, 2024 annual meeting.
Issued $700M (incl. $100M greenshoe) of 2.50% Convertible Senior Notes due June 1, 2029.
Haemonetics prices $600M 2.50% convertible notes due 2029; to repurchase $200M of 2026 notes
$600M 2.50% convertible senior notes due 2029 priced; initial conversion price ~$117.12/share (30% premium over $90.09 closing).
Haemonetics announces $525M convertible senior notes offering due 2029
$525M principal amount of convertible senior notes due 2029, with option for additional $75M.
Haemonetics announces Q4 and FY2024 financial results; details not available in this filing
Press release dated May 9, 2024, reports results for quarter and fiscal year ended March 30, 2024.
Haemonetics enters $1B credit agreement; $250M term loan, $750M revolver due 2029
New $250M senior unsecured term loan retires existing term loan under 2022 credit agreement.
Haemonetics completes acquisition of Attune Medical (Advanced Cooling Therapy)
Acquisition closed on April 1, 2024; terms consistent with March 5, 2024 8-K disclosure.
Haemonetics to acquire Attune Medical for $160M upfront; device complements EP portfolio
Upfront cash $160M plus contingent consideration based on sales growth and milestones.
On April 27, 2026, Charles J. Dockendorff informed Haemonetics Corporation (the “Company”) that he will not stand for re-election at the Company’s 2026 Annual Meeting of Shareholders (the “2026 Annual Meeting”).
On March 3, 2025, Haemonetics Corporation (the “Company”) announced the appointment of Frank W. Chan, Ph.D. as its Executive Vice President, Chief Operating Officer, effective April 7, 2025.
Josep Llorens, Executive Vice President, Global Manufacturing and Supply Chain, has notified Haemonetics Corporation (the “Company”) of his decision to retire from the Company effective July 11, 2025.
Anila Lingamneni, Executive Vice President, Chief Technology Officer, will leave Haemonetics Corporation (the “Company”) on November 1, 2024.
Max materiality 0.70 · Median 0.50 · Most common event earnings